Special Report

Mona Shahriari, MD, and Andrew Mastro, MS, PA-C, discuss challenges in long-term management of atopic dermatitis and navigating switching therapeutic classes.

Christie Ballantyne, MD, and Viet Le, DMSc, PA-C, discuss the changing landscape of familial chylomicronemia syndrome management and how the introduction of plozasiran impacts care.

A structured outline of expert discussion points, data highlights, and launch scheduling related to emerging treatments—particularly remibrutinib—for chronic spontaneous urticaria (CSU).

A trio of advanced heart failure specialists discusses how the approval of finerenone and other recent updates impact management for heart failure with mildly reduced or preserved ejection fraction.

A trio of experts in pulmonology discuss the role of monoclonal antibodies in the management of chronic obstructive pulmonary disease following the FDA approval of mepolizumab (Nucala).

A multipart video series featuring perspectives from leading experts in dermatology on the role of lebrikizumab (Ebglyss) in patients with atopic dermatitis and skin of color.

Steven Fein, MD, discusses clinically relevant updates in hematology from the American Society of Hematology meeting and the rest of 2024.

Ophthalmologists Veeral Sheth, MD, and David Lally, MD provide an overview of geographic atrophy, an advanced stage of dry age-related macular degeneration, and describe the unfolding treatment landscape for the disease.

Expert advanced practice providers in the field of dermatology are sharing their experience and knowledge in treating patients with hidradenitis suppurativa. They are discussing the impact of this chronic disease on the quality of life of patients, as well as new insights in the pathophysiology of hidradenitis suppurativa guiding the development of novel treatments.

Dermatologists Drs Neal Bhatia and Dr Leon Kircik discuss topical treatments and how recent approval of a novel topical PDE4 inhibitor is likely to impact the treatment landscape of plaque psoriasis.

David P. Hudesman, shares insight on long-term extension data and clinical implications from ACG 2022 on the use of ustekinumab for the management of ulcerative colitis.

Insight from gastroenterology specialists on implications for treating patients with ulcerative colitis with newer novel therapies as recently presented at DDW 2021.